News
SNYNF
88.50
NaN%
--
AI Daily: Amazon’s AWS commits $1B toward new unit
TipRanks · 1d ago
Anthropic takes aim at pharma industry with Claude Science, STAT reports
TipRanks · 1d ago
Vertex Pharmaceuticals Has One Of The Widest And Most Durable Moats In Biotech
Seeking Alpha · 1d ago
TG Therapeutics Surged 88%: Time To Be More Careful (Rating Downgrade)
Seeking Alpha · 2d ago
Weekly Report: what happened at SNYNF last week (0622-0626)?
Weekly Report · 2d ago
Sanofi: Dupixent Risks Overstated, Valuation Disconnect Creates Opportunity
Seeking Alpha · 6d ago
MacroGenics: 'Hold' Potential Best-In-Class B7-H3 ADC And TZIELD Payment
Seeking Alpha · 06/24 18:35
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials
TipRanks · 06/23 18:35
Viatris Soared 54%: Time To Be More Careful (Rating Downgrade)
Seeking Alpha · 06/23 16:55
Moderna: The Comeback Is Now In Full Swing
Seeking Alpha · 06/23 12:21
MacroGenics to receive $24.5M milestone payment from Sanofi
TipRanks · 06/22 20:45
Sanofi investors likely to view new R&D head as a positive, says BofA
TipRanks · 06/22 13:26
Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and Ocular Therapeutix (OCUL)
TipRanks · 06/22 13:11
Weekly Report: what happened at SNYNF last week (0615-0619)?
Weekly Report · 06/22 09:53
Sanofi 'Strong Buy': Continued Dupxient Sales Growth And Sarclisa OBI First
Seeking Alpha · 06/15 20:49
Sanofi price target lowered to EUR 95 from EUR 100 at Deutsche Bank
TipRanks · 06/15 16:16
CMS proposes to lock in lower prices in Medicare drug price negotiation program
TipRanks · 06/15 16:10
Weekly Report: what happened at SNYNF last week (0608-0612)?
Weekly Report · 06/15 09:54
Deutsche Bank Keeps Their Buy Rating on Sanofi (SNYNF)
TipRanks · 06/15 07:55
Sanofi type 1 diabetes therapy Tzield approved in U.S. for stage 3 of the disease
Seeking Alpha · 06/13 14:14
More
Webull provides a variety of real-time SNYNF stock news. You can receive the latest news about Sanofi FR through multiple platforms. This information may help you make smarter investment decisions.
About SNYNF
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.